Remedy, the dermatologist-developed skin care brand founded by Muneeb Shah, DO, has closed a Series A funding round of more than $20 million led by L Catterton, with participation from existing investor Norwest and new investor Sonoma Brands Capital, positioning the fast-growing company for its next phase of expansion.
The investment follows a breakout two years for Remedy, which has rapidly emerged as one of the most closely watched challenger brands in dermocosmetics. Since launching in March 2024, the company has built momentum through a science-backed, education-first approach that rejects the industry's reliance on complicated routines, trend-driven ingredients, and prestige pricing.
The brand's portfolio targets issues commonly seen in dermatology clinics, including dark spots, dryness, sensitive skin, fine lines, dullness and keratosis pilaris.Remedy
Shah, whose evidence-based content reaches more than 20 million followers, built Remedy around real skin concerns rather than single-ingredient trends. Its portfolio targets issues commonly seen in dermatology clinics, including dark spots, dryness, sensitive skin, fine lines, dullness and keratosis pilaris.
The funding arrives on the heels of several major milestones for the brand. In late 2025, Remedy expanded nationwide into Target, positioning itself as a mass-market alternative to traditional prestige skin care while lowering prices on select products through retail scale efficiencies. Earlier this year, the company launched its first national advertising campaign, a humorous, Zoolander-inspired critique of skin care complexity backed by a more than $500,000 media investment. The brand also recently expanded its treatment lineup with a dermatologist-designed eye cream targeting multiple causes of dark circles in a single formula.
Shah, whose evidence-based content reaches more than 20 million followers, built Remedy around real skin concerns rather than single-ingredient trends. Remedy
According to the company, the new capital will be used to accelerate clinical research, expand its pipeline of dermatologist-developed products, strengthen formulation and testing capabilities, and support growing demand across direct-to-consumer, Amazon and Target channels.
L Catterton partner Tehmina Haider said the firm believes Remedy is helping define the next generation of dermocosmetics by combining clinical credibility, advanced ingredient technology and accessible pricing. The investment underscores continued investor interest in expert-led beauty brands that pair strong educational platforms with consumer-friendly product innovation.
As consumers increasingly seek simplified routines and clinically grounded solutions, Remedy is betting that dermatology-backed efficacy—not skin care excess—will be the foundation of its long-term growth.
